Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler
Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...
Drug
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...
Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...
Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025
China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...
Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed
China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...
Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market approval filing for a...
CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough...
Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...
BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease
Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...
GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...
Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...